- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Physicians choose valued sales forces
Physicians in nine specialty groups collectively agreed for the third consecutive year that Pfizer Labs' sales force is the most valuable, according to health care consulting firm Scott-Levin's study "Sales Force Structures & Strategies 1997-1998."
Physicians in nine specialty groups collectively agreed for the third consecutive year that Pfizer Labs' sales force is the most valuable, according to health care consulting firm Scott-Levin's study "Sales Force Structures & Strategies 1997-1998."
Strong product lines helped Pfizer reps cinch their grip on the number one spot, according to Scott-Levin. Pfizer launched Aricept, an Alzheimer's disease therapy, and received a new indication for its antidepressant Zoloft.
Pfizer Labs' sales force had the added bonus of co-promoting Lipitor, a powerful cholesterol-reducer manufactured by Parke-Davis.
Merck's sales force was ranked number one by internal medicine specialists, cardiologists, rheumatologists and infectious disease specialists.
Wyeth-Ayerst's sales force was preferred by obstetricians and gynecologists, orthopedic surgeons and physical medicine and rehabilitation specialists.
SmithKline Beecham's sales force ranked first with general surgeons and neurosurgeons. Schering Plough was first with allergists and otorhinolaryngologists. Astra Merck was a favorite with gastroenterologists and Lilly was tops with psychiatrists. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
